CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Get the annual and quarterly balance sheet of Alnylam Pharmaceuticals, Inc. (ALNY) including details of assets, liabilities and shareholders' equity.

The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...